FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results

Author： Pacini P.   Rinaldini M.   Algeri R.   Guarneri A.   Tucci E.   Barsanti G.   Neri B.   Bastiani P.   Marzano S.   Fallai C.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.36, Iss.8, 2000-05, pp. : 966-975

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients

By Romanini A.   Tanganelli L.   Carnino F.   Fanucchi A.   Lionetto R.   Pastorino S.   Cosio S.   Gadducci A.   Conte P.F.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 354-359

Elsevier

Access to resources Recommend Favorite

Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor

By Stoger H.   Samonigg H.   Krainer M.   Ploszczynski M.   Nirnberger G.   Maca S.   Hehenwarter W.   Wirth M.   Schuller J.   Vavra N.   Scheithauer W.   Kornek G.   Stierer M.   Zielinski C.C.  

European Journal of Cancer, Vol. 34, Iss. 4, 1998-03 ,pp. : 482-488

Elsevier

Access to resources Recommend Favorite

Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon- -2c in patients with advanced colorectal cancer: final results of a randomised phase III study

By Hausmaninger H.   Moser R.   Samonigg H.   Mlineritsch B.   Schmidt H.   Pecherstorfer M.   Fridrik M.   Kopf C.   Nitsche D.   Kaider A.   Ludwig H.  

European Journal of Cancer, Vol. 35, Iss. 3, 1999-03 ,pp. : 380-385

Elsevier

Access to resources Recommend Favorite

Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells

By Silvestrini R.   Gornati D.   Zaffaroni N.   Bearzatto A.   de Marco C.  

Breast Cancer Research and Treatment, Vol. 42, Iss. 2, 1997-01 ,pp. : 103-112

Springer Publishing Company

Access to resources Recommend Favorite

Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer-a randomised study with more than 10 years follow-up from the danish breast cancer cooperative gr

By Andersson M.   Lindegaard Madsen E.   Overgaard M.   Rose C.   Dombernowsky P.   Mouridsen H.T.  

European Journal of Cancer, Vol. 35, Iss. 1, 1999-01 ,pp. : 39-46

Elsevier

Access to resources Recommend Favorite